{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458638966
| image = 
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[CD4]]
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 156586-90-2
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03420
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}

'''Cedelizumab''' is a [[monoclonal antibody]] acting on the [[immune system]].<ref>[http://apps.who.int/medicinedocs/index/assoc/s14167e/s14167e.pdf WHO Drug Information]</ref> Possible indications include the prevention of [[organ transplant]] rejections and the treatment of [[autoimmune disease]]s.<ref>{{cite book|title=The NDA pipeline|publisher=F-D-C Development Corporation|year=2001|url=https://books.google.com/books?id=xAttAAAAMAAJ&dq=cedelizumab}}</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}